Psma-targeted radiopharmaceuticals for treatment of cancer
A pharmaceutical formulation with 225Ac-PSMA-I&T targets PSMA-expressing cancer cells, addressing the inefficiencies of current treatments by enhancing therapeutic efficacy through targeted delivery.
Patent Information
- Application Number
- SA1120260139
- Authority / Receiving Office
- SA · SA
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-01-06
- Publication Date
- 2026-10-05
AI Technical Summary
Current cancer treatments using radioactive conjugates are not effectively targeting cancer cells that genetically express PSMA, leading to suboptimal therapeutic efficacy.
Development of a pharmaceutical formulation containing a radioactive conjugate of 225Ac in the I variant, such as 225Ac-PSMA-I&T, which is specifically designed to target cancer cells expressing PSMA, utilizing a formulation that includes sodium acetate, sodium ascorbate L, and diethylene triamine pentaacetate (DTPA) without gentisate, enhancing therapeutic efficacy.
The formulation effectively targets and treats cancer cells expressing PSMA with improved therapeutic outcomes, including reduced tumor volume and growth, by leveraging the specificity of 225Ac-PSMA-I&T.
Abstract
Description
This finding relates to certain pharmaceutical formulations that include a radioactive conjugate of 225Ac in the I variant, such as 225Ac-PSMA-I&T, which can be used to treat cancer that genetically expresses PSMA with improved therapeutic efficacy, compared to current treatments. Definitions Chemical terminology The term "isomer," as used here, refers to any chemical isomer, stereoisomer, homolog, or diploid of a compound. A compound with formula I is known to contain one or more chiral centers and can therefore exist as stereoisomers, such as diploids (e.g., isomers (i.e., (+) or (-))). Unless otherwise stated, the chemical structures described here include all corresponding stereomeric isomers, i.e., the stereomerically pure form (e.g., geometrically pure, stereomerically pure, or diploid pure) and a mixture of isomers and stereoisomers, such as racemes. The combinations of isomers and stereoisomers of compounds can usually be separated into their isomer or stereoisomer components using well-known methods, such as chiral-phase gas chromatography, chiral-phase high-performance liquid chromatography, crystallization of the compound as a chiral salt complex, or crystallization of the compound in a chiral solvent.Stereoisomers and stereoisomers can also be obtained from stereotactically or stereotactically pure reaction media, reagents, or catalysts using well-known asymmetric synthetic methods. The term "stereoisomer," as used here, refers to all the different isomeristic and conformational forms that a compound (such as a compound of any formula described here) may possess, and in particular all stereoisomers, conformations, and / or homologs of the basic molecular structure. Some compounds may exist in different chemically homologous forms, and all are included within the scope of this disclosure. The term "double isomer," as used here, refers to spatial isomers that are not mirror images of each other and cannot be superimposed onto each other. The term “isomer,” as used here, refers to each optically active form of the compound, having an optical purity or isomer excess (as determined by standard methods in the field) of not less than 80% (i.e., not less than 90% of one isomer and not more than 10% of the other), preferably not less than 90%, and most preferably not less than 98%. Other terms As used here, the terms “approximately” or “about” refer to a variation of ±10% of the stated quantified value (including the stated quantified value itself) unless otherwise stated or inferred from the context. For example, unless otherwise stated or inferred from the context, a concentration of approximately 100 μg / mL refers to a concentration range of 100 ± 10% μg / mL, i.e., from 90 μg / mL to 110 μg / mL, encompassing both values. As used here, "giving" an agent to a patient involves contact between the patient's cells and the agent. The term "cancer" refers to any cancer resulting from the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, fibroids, leukemias, and lymphomas. "Solid tumor cancer" is cancer that consists of an abnormal mass of tissue, such as fibroids, carcinomas, and lymphomas. "Hematological cancer" or "liquid cancer," as they are sometimes used interchangeably here, is cancer that occurs in body fluids, such as lymphomas and leukemias. The term "chelate" as used here refers to an organic compound or part thereof that can be bonded to a central metal atom or a radioactive metal at two or more points. The term "conjugate," as used here, refers to a molecule containing a chelating group or a metal complex thereof, a bonding group, and may optionally contain a therapeutic moiety or a target moiety. As used here, the term "compound" includes all stereoisomers, geometric isomers, and chemical isomers of the structures shown. The compounds described here may be asymmetric (i.e., contain one or more stereocenters). All stereoisomers, such as isomers and diisomers, are intended unless otherwise stated. Compounds in this disclosure containing asymmetrically substituted carbon atoms in optically active or racemic forms may be isolated. Methods for preparing optically active forms from optically active precursors are well-established in the field, such as the separation of racemic mixtures or stereoselective synthesis. Several geometric isomers of olefins, C=N double bonds, and the like may also be present in the compounds described here, and all such stable isomers are considered in this disclosure. The cis and trans geometric isomers of the compounds in this disclosure are described and may be isolated as combinations of isomers or as separate isomer forms. The compounds identified in this study also include isomorphic forms. Isomorphic forms result from the substitution of a single bond with an adjacent double bond and the accompanying proton migration. Isomorphic forms include proton isomers, which are isomerized proton states with the same empirical formula and net charge. Examples of proton isomers include ketone-enol pairs, amide-imide pairs, lactam-lactam pairs, amide-imide pairs, enamine-imine pairs, and heterocyclic systems where a proton can occupy two or more positions in a heterocyclic ring system, such as 1H- and 3H-imidazole, 1H- and 2H-triazole, 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. The shapes can be chemically homologous in equilibrium or spatially locked into a single shape by appropriate substitution. As used here, the terms “decreasing,” “decreasing,” “increasing,” “increasing,” or “decreasing” and “decreasing” (for example, in reference to therapeutic outcomes or effects) have meanings relative to a reference level. In some embodiments, this reference level may be a level determined by using the method described with a control group in an experimental animal model or clinical trial. In some embodiments, the reference level may be a level present in the same subject before or at the start of treatment. In some embodiments, the reference level is the average level in a group not treated with the method described. The term “effective amount” of an active ingredient (e.g., any of the above-mentioned ligands), as used here, refers to the amount sufficient to achieve beneficial or desirable results, such as clinical outcomes. Thus, the “effective amount” depends on the context in which it is applied. The term "pharmaceutical formulation," as used here, refers to a formulation containing the compound described herein that has been prepared with a pharmacologically acceptable excipient. In some embodiments, the pharmaceutical formulation is manufactured or sold with the approval of a government regulatory agency as part of a therapeutic regimen for the treatment of disease in mammals. Pharmaceutical formulations may be prepared, for example, for oral administration in a unit dosage form (e.g., tablet, capsule, coated tablet, gelatin capsule, or syrup); for topical administration (e.g., cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate embolites and in a solvent system suitable for intravenous use); or in any other formulation described herein. The term "pharmaceuticalally acceptable excipient," as used here, refers to any component other than the compounds described herein (e.g., an excipient capable of suspending or dissolving the active compound) that has non-toxic and non-inflammatory properties in the patient. Pharmaceuticalally acceptable excipients are typically added to a pharmaceutical product to aid formulation, stabilization, or drug delivery. Excipients may include, for example: anti-adhesives, antioxidants, binders, coatings, compression aids, dispersants, dyes (colors), softeners, emulsifiers, fillers (thinners), coatings, flavorings, fragrances, lubricants (flow enhancers), lubricants, preservatives, printing inks, radiation shielding agents, absorbents, suspending or dispersing agents, sweeteners, or hydration water.Examples of excipients include, but are not limited to: ascorbic acid, histidine, phosphate buffer solution, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, and sodium starch. Glycolates, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol. The term "pharmaceuticalally acceptable salt," as used here, refers to salts of the compounds described herein that are, within the bounds of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, or an allergic response. Pharmaceuticalally acceptable salts are well-established in the field. For example, they have been described in Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977, and in Pharmaceutical Salts: Properties, Selection, and Use (Eds. PH Stahl and CG Wermuth), Wiley-VCH, 2008. Salts may be prepared on-site during the final isolation and purification of the compounds described herein or separately by reacting a free base group with a suitable organic acid. Compounds may contain ionizable groups, allowing them to be prepared as pharmacologically acceptable salts. These salts may be acid addition salts, involving inorganic or organic acids, or, in the case of acidic forms of the compounds, salts may be prepared from inorganic or organic bases. Compounds prepared or used as pharmacologically acceptable salts are often those prepared as addition products of pharmacologically acceptable acids or bases. Suitable and well-known pharmacologically acceptable bases and acids include hydrochloric, sulfuric, hydrobromic, acetic, lactic, citric, or tartaric acids for forming acid addition salts, and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, and various amines for forming basic salts. Methods for preparing suitable salts are well-established in the field. The clarifying acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzensulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanpropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptones, glycerol phosphate, hemisulfate, heptones, hexanoates, hydrobromide, hydrochloride, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurates, lauryl sulfate, maleates, fillers, malonates, methanesulfonate, 2-naphthalenesulfonate, nicotinates, nitrates, oleates, oxalates, palmitates, pimoates, pectins, and persulfates. 3-phenylpropionate, phosphates, picrates, bivalate, propionates, esters, succinates, sulfates, tartars, thiocyanates, toluene sulfonates, undecanoates, and valerates, among other salts.Illustrative examples of alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amino cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine. The term “radioactive pharmaceutical” or “radioactive conjugate,” as used here, refers to any compound or conjugate that includes a radioactive isotope or radionuclide, such as the radioisotope or radionuclide described herein. The term “prodrug,” as used here, refers to a pharmaceutically inactive compound or drug that is given in its inactive form and is converted into a pharmaceutically active drug within the body through metabolism or other chemical reactions. The term "aqueous formulation," as used here, refers to a liquid or semi-solid dosage form that contains water as the solvent or base medium. Examples of aqueous formulations include solutions, suspensions, emulsions, and gels. In a solution, the drug or active ingredient is dissolved in water; in a suspension, the drug is suspended in water with the help of a stabilizer. In an emulsion, the drug is dispersed in water using a surfactant and an emulsifying agent. A gel is a semi-solid aqueous formulation that contains a gelling agent to provide a thickened consistency. The term "largely free," as used here, when applied in relation to a particular component of a formulation (e.g., a pharmaceutical formulation largely free of gentisate), refers to a formulation into which none of the stated component has been added essentially. When a formulation is "largely free" of a particular component, it appropriately contains no more than 0.001% by weight of the stated component, appropriately no more than 0.0001% by weight of the stated component, appropriately no more than 0.00001% by weight of the stated component, appropriately no more than 0.000001% by weight of the stated component, appropriately no more than 0.0000001% by weight of the stated component, appropriately no more than 0.0000001% by weight of the stated component, and most appropriately no more than 0.0001 parts per billion (by weight). As used here, and as is well understood in the field, “treating” a condition or “curing” a condition (e.g., the conditions described here, such as cancer) means an approach to obtaining beneficial or desirable outcomes, such as clinical results. Beneficial or desirable outcomes may include, but are not limited to, the relief or improvement of one or more symptoms or conditions; a reduction in the extent of the disease, disorder, or condition; stabilization (i.e., no worsening) of the disease, disorder, or condition; prevention of the spread of the disease, disorder, or condition; delay or slow the progression of the disease, disorder, or condition; improvement or relief of the disease, disorder, or condition; and a cure (either partial or complete), whether detectable or undetectable. In the context of cancer treatment, “improvement” may include, for example, a reduction in the incidence of metastases, a reduction in tumor volume, a reduction in tumor vascularization, and / or a reduction in the rate of tumor growth. “Relief” of a disease, disorder, or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are reduced and / or the course of progression is slowed or prolonged, compared to the extent or course in the absence of treatment. pharmaceutical formulations This discovery provides pharmaceutical formulations containing the radioactive conjugate of 225Ac in the form I, in the absence of the gentisate complex. These formulations can be used to treat a patient with cancer who is genetically expressive of PSMA. The pharmaceutical composition mentioned here includes: (a) A radioactive conjugate of 225Ac or a pharmaceutically acceptable salt thereof, The radioactive conjugate of 225Ac includes 225Ac chelated with a compound of formula I, or a prodrug of it: (I), Where the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical formulation at a concentration of approximately 1 microgram / milliliter to approximately 100 micrograms / milliliter, or in an amount that provides a radioactivity concentration of approximately 10 microcuries / milliliter to approximately 1000 microcuries / milliliter of the pharmaceutical formulation; (b) Sodium acetate, where sodium acetate is present in the pharmaceutical formulation at a concentration of approximately 1 mg / mL to approximately 400 mg / mL, (c) Sodium ascorbate L, where sodium ascorbate L is present in the pharmaceutical formulation at a concentration of approximately 40 mg / mL to approximately 150 mg / mL; and (d) Diethylene triamine pentaacetate (DTPA), where DTPA is present in the pharmaceutical formulation at a concentration of approximately 5 micrograms / milliliter to approximately 60 micrograms / milliliter, The pharmaceutical formulation is an aqueous formula and free of gentisate. In some versions, the pharmaceutical formula mentioned here contains: (a) A radioactive conjugate of 225Ac or a pharmaceutically acceptable salt thereof, The radioactive conjugate of 225Ac includes 225Ac chelated with a compound of formula I, or a prodrug of it: (I), Where the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical formulation at a concentration of approximately 1 microgram / milliliter to approximately 100 micrograms / milliliter, or in an amount that provides a radioactivity concentration of approximately 10 microcuries / milliliter to approximately 1000 microcuries / milliliter of the pharmaceutical formulation; (b) Sodium acetate, where sodium acetate is present in the pharmaceutical formulation at a concentration of approximately 1 mg / mL to approximately 400 mg / mL, (c) Sodium ascorbate L, where sodium ascorbate L is present in the pharmaceutical formulation at a concentration of approximately 40 mg / mL to approximately 150 mg / mL; and (d) Diethylene triamine pentaacetate (DTPA), where DTPA is present in the pharmaceutical formulation at a concentration of approximately 5 micrograms / milliliter to approximately 60 micrograms / milliliter, The pharmaceutical formulation is an aqueous formula and largely free of gentisate. Formula I compounds include various stereoisomers, such as diisomers or isomers, of the formula I structure. In some embodiments, the radioactive conjugate of 225Ac includes 225Ac chelated with the following structure, i.e., PSMA I&T: . In certain embodiments, the radioactive conjugate of 225Ac includes 225Ac chelated with the following structure, i.e., PSMA I&T in an enantiomeric form-(R) with respect to the spatial center on the carbon adjacent to DOTA: . In certain embodiments, the radioactive conjugate of 225Ac includes 225Ac chelated with the following structure, i.e., PSMA I&T in an isomer-(S) with respect to the spatial center on the carbon adjacent to DOTA: . In some formulations, the radioactive conjugate of 225Ac or its pharmacologically acceptable salt is present in the pharmaceutical formulation at concentrations of approximately 1 µg / mL to approximately 100 µg / mL, such as approximately 2 µg / mL to approximately 90 µg / mL, approximately 3 µg / mL to approximately 80 µg / mL, approximately 4 µg / mL to approximately 60 µg / mL, approximately 5 µg / mL to approximately 50 µg / mL, approximately 6 µg / mL to approximately 40 µg / mL, approximately 7 µg / mL to approximately 30 µg / mL, approximately 8 µg / mL to approximately 20 µg / mL, approximately 8 µg / mL to approximately 10 µg / mL, and approximately 7 µg / mL to approximately 10 µg / mL. 1 microgram / mL to approximately 10 micrograms / mL, approximately 6 micrograms / mL to approximately 10 micrograms / mL, approximately 5 micrograms / mL to approximately 10 micrograms / mL, approximately 4 micrograms / mL to approximately 10 micrograms / mL, approximately 3 micrograms / mL to approximately 10 micrograms / mL, approximately 2 micrograms / mL to approximately 10 micrograms / mL, approximately 1micrograms / mL to approximately 10 micrograms / mL, approximately 10 micrograms / mL to approximately 15 micrograms / mL, approximately 15 micrograms / mL to approximately 20 micrograms / mL, approximately 20 micrograms / mL to approximately 25 micrograms / mL, approximately 25 micrograms / mL to approximately 30 micrograms / mL, approximately 30 micrograms / mL to approximately 35 micrograms / mL, approximately 35 micrograms / mL to approximately 40 micrograms / mL, approximately 40 micrograms / mL to approximately 45 micrograms / mL, approximately 45 micrograms / mL to approximately 50 micrograms / mL, approximately 50 micrograms / mL to approximately 55 micrograms / mL, approximately 55 micrograms / mL to approximately 60 micrograms / mL, approximately 60 micrograms / mL to approximately 65 micrograms / mL, approximately 65 micrograms / mL to approximately 70 micrograms / mL, approximately 70 micrograms / mL to approximately 75 micrograms / mL, approximately 75 micrograms / mL to approximately 80 micrograms / mL, approximately 80 micrograms / mL to approximately 85 micrograms / mL, approximately 85 micrograms / mL to approximately 90 micrograms / mL, approximately90 micrograms / mL to approximately 95 micrograms / mL, approximately 95 micrograms / mL to approximately 100 micrograms / mL, approximately 10 micrograms / mL to approximately 20 micrograms / mL, approximately 20 micrograms / mL to approximately 30 micrograms / mL, approximately 30 micrograms / mL to approximately 40 micrograms / mL, approximately 40 micrograms / mL to approximately 50 micrograms / mL, approximately 50 micrograms / mL to approximately 60 micrograms / mL, approximately 60 micrograms / mL to approximately 70 micrograms / mL, approximately 70 micrograms / mL to approximately 80 micrograms / mL, approximately 80 micrograms / mL to approximately 90 micrograms / mL, or approximately 90 micrograms / milliliter to approximately 100 micrograms / milliliter. In certain embodiments, the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical formulation at a concentration of approximately 5 micrograms / mL to approximately 50 micrograms / mL (e.g., approximately 5 micrograms / mL to approximately 45 micrograms / mL, approximately 5 micrograms / mL to approximately 40 micrograms / mL, approximately 5 micrograms / mL to approximately 35 micrograms / mL, approximately 5 micrograms / mL to approximately 30 micrograms / mL, approximately 5 micrograms / mL to approximately 25 micrograms / mL, approximately 5 micrograms / mL to approximately 20 micrograms / mL). In certain embodiments, the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical formulation at a concentration of approximately 5 micrograms / milliliter to approximately 20 micrograms / milliliter (e.g., approximately 5 micrograms / milliliter to approximately 10 micrograms / milliliter). In certain formulations, the radioactive conjugate of 225Ac or its pharmacologically acceptable salt is present in the pharmaceutical formulation at a concentration of approximately 7 µg / mL to approximately 9 µg / mL. In certain formulations, the radioactive conjugate of 225Ac or its pharmacologically acceptable salt is present in the pharmaceutical formulation at a concentration of approximately 7 µg / mL to approximately 8 µg / mL (e.g., 7.0 µg / mL, 7.1 µg / mL, 7.2 µg / mL, 7.3 µg / mL, 7.4 µg / mL, 7.5 µg / mL, 7.6 µg / mL, 7.7 µg / mL, 7.8 µg / mL, 7.9 µg / mL, or 8.0 µg / mL). In certain embodiments, the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical formulation at a concentration of approximately 8 micrograms / mL to approximately 9 micrograms / mL (e.g., 8.1 micrograms / mL, 8.2 micrograms / mL, 8.3 micrograms / mL, 8.4 micrograms / mL, 8.5 micrograms / mL, 8.6 micrograms / mL, 8.7 micrograms / mL, 8.8 micrograms / mL, 8.9 micrograms / mL, or 9.0 micrograms / milliliter). In some embodiments, the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in quantities that provide a radioactivity concentration of approximately 10 µCi / mL to approximately 1000 µCi / mL, such as approximately 10 µCi / mL to approximately 50 µCi / mL, approximately 50 µCi / mL to approximately 100 µCi / mL, approximately 100 µCi / mL to approximately 150 µCi / mL, approximately 150 µCi / mL to approximately 200 µCi / mL, approximately 200 µCi / mL to approximately 250 µCi / mL, approximately 250 µCi / mL to approximately 300 µCi / mL, and approximately 300 µCi / mL to approximately 350 µC / mL, approximately 350 µC / mL to approximately 400 µC / mL, approximately 400 µC / mL to approximately 450 µC / mL, approximately 450 µC / mL to approximately 500 µC / mL, approximately 500 µC / mL to approximately 550 µC / mL, approximately 550 µC / mL to approximately 600 µC / mL, approximately 600 µC / mL to approximately 650 µC / mL, approximately 650 µC / mL toAbout 700 microcuries / mL, about 700 microcuries / mL to about 750 microcuries / mL, about 750 microcuries / mL to about 800 microcuries / mL, about 800 microcuries / mL to about 850 microcuries / mL, about 850 microcuries / mL to about 900 microcuries / mL, about 900 microcuries / mL to about 950 microcuries / mL, or about 950 microcuries / mL to about 1000 microcuries / mL. In the pharmaceutical formulations mentioned here, sodium acetate is present as a pH regulator or stabilizer. Other equivalent excipients that may be used as pH regulators or stabilizers include, but are not limited to, acetic acid, sodium ascorbate, ascorbic acid, fumaric acid, propionic acid, ammonium sulfate, ammonium hydroxide, arginine, aspartic acid, benzenesulfonic acid, sodium benzoate, sodium bicarbonate, boric acid, sodium carbonate, carbonic acid, diethanolamine, citrate acid, hydrobromic acid, glycine, histidine, sodium lactate, (L)-lysine, malic acid, methanesulfonic acid, phosphoric acid, monobasic sodium phosphate, tribasic sodium phosphate, dibasic sodium phosphate, sodium hydroxide, sodium / disodium succinate, sulfuric acid, sodium tartrate, tartaric acid, and tromethamine. (Tris). In some formulations, sodium acetate is present in pharmaceutical formulations at concentrations of approximately 5 mg / mL to approximately 200 mg / mL, such as approximately 5 mg / mL to approximately 15 mg / mL, approximately 15 mg / mL to approximately 25 mg / mL, approximately 25 mg / mL to approximately 35 mg / mL, approximately 35 mg / mL to approximately 45 mg / mL, approximately 45 mg / mL to approximately 55 mg / mL, approximately 55 mg / mL to approximately 65 mg / mL, approximately 65 mg / mL to approximately 75 mg / mL, approximately 75 mg / mL to approximately 85 mg / mL, approximately 85 mg / mL to approximately 95 mg / mL, and approximately 95 mg / mL to approximately 95 mg / mL. mg / mL to approximately 100 mg / mL, approximately 100 mg / mL to approximately 110 mg / mL, approximately 110 mg / mL to approximately 120 mg / mL, approximately 120 mg / mL to approximately 130 mg / mL, approximately 130 mg / mL to approximately 140 mg / mL, approximately 140 mg / mL to approximately 150 mg / mL, approximately 150 mg / mL to approximately 160 mg / mL, approximately 160 mg / mL to approximately 170 mg / mL, approximately 170 mg / mL to approximately 180 mg / mL, approximately 180mg / mL to about 190 mg / mL, or about 190 mg / mL to about 200 mg / mL. In certain formulations, sodium acetate is present in the pharmaceutical formulation at a concentration of approximately 6 mg / mL to approximately 10 mg / mL. In certain formulations, sodium acetate is present in the pharmaceutical formulation at a concentration of approximately 9 mg / mL. In the pharmaceutical formulations listed here, sodium ascorbate L is present as a pH regulator or radioprotective agent. Equivalent excipients to sodium ascorbate L include, but are not limited to, ascorbic acid, sodium acetate, sodium benzoate, sodium bicarbonate, sodium carbonate, tribasic sodium phosphate acid, dibasic sodium phosphate acid, monobasic sodium phosphate acid, sodium tartrate, sodium lactate, sodium succinate, and sodium disuccinate. In some formulations, sodium ascorbate L is present in pharmaceutical formulations at concentrations of approximately 45 mg / mL to approximately 100 mg / mL, such as approximately 45 mg / mL to approximately 50 mg / mL, approximately 50 mg / mL to approximately 55 mg / mL, approximately 55 mg / mL to approximately 60 mg / mL, approximately 60 mg / mL to approximately 65 mg / mL, approximately 65 mg / mL to approximately 70 mg / mL, approximately 70 mg / mL to approximately 75 mg / mL, approximately 75 mg / mL to approximately 80 mg / mL, approximately 80 mg / mL to approximately 85 mg / mL, and approximately 85 mg / mL to approximately 90 mg / mL. 90 mg / mL to about 95 mg / mL, or about 95 mg / mL to about 100 mg / mL. In certain formulations, sodium ascorbate L is present in the pharmaceutical formulation at a concentration of approximately 45 mg / mL to approximately 60 mg / mL. In certain formulations, sodium ascorbate L is present in the pharmaceutical formulation at a concentration of approximately 50 mg / mL. In the pharmaceutical formulations listed here, diethylenediaminepentaacetic acid (DTPA) is present as a metal chelating agent. Equivalent metal chelating agents to DTPA include, but are not limited to, diethylenediaminepentaacetic acid, ethylenediaminetetraacetic acid (EDTA), 6,6'-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecene-7,16-diyl)bis(methylene))dipicolinenic acid (Macropa), or any pharmaceutically acceptable salt thereof. In some incarnations, DTPA is the calcium trisodium salt hydrate (DTPA-CTSH) or the pentasodium salt (DTPA-PS). In certain incarnations, DTPA is DTPA-PS. In some embodiments, DTPA (such as DTPA-PS) is present in the pharmaceutical formulation at a concentration of approximately 20 micrograms / mL to approximately 55 micrograms / mL, such as approximately 20 micrograms / mL to approximately 25 micrograms / mL, approximately 25 micrograms / mL to approximately 30 micrograms / mL, approximately 30 micrograms / mL to approximately 35 micrograms / mL, approximately 35 micrograms / mL to approximately 40 micrograms / mL, approximately 40 micrograms / mL to approximately 45 micrograms / mL, approximately 45 micrograms / mL to approximately 50 micrograms / mL, or approximately 50 micrograms / mL to approximately 55 micrograms / mL. In certain formulations, DTPA (such as DTPA-PS) is present in the pharmaceutical formulation at a concentration of approximately 45 micrograms / mL to approximately 52 micrograms / mL. In certain formulations, DTPA (such as DTPA-PS) is present in the pharmaceutical formulation at a concentration of approximately 50 micrograms / milliliter. The pharmaceutical formulations mentioned here may contain ethanol. In some formulations, the pharmaceutical formulations are ethanol-free. In some formulations, pharmaceutical preparations also contain ethanol, where the ethanol is present in concentrations of approximately 20 mg / mL to approximately 100 mg / mL, such as approximately 40 mg / mL to approximately 100 mg / mL, approximately 60 mg / mL to approximately 100 mg / mL, approximately 80 mg / mL to approximately 100 mg / mL, approximately 20 mg / mL to approximately 40 mg / mL, approximately 40 mg / mL to approximately 60 mg / mL, approximately 60 mg / mL to approximately 80 mg / mL, approximately 80 mg / mL to approximately 100 mg / mL, approximately 20 mg / mL to approximately 30 mg / mL, and approximately 30 mg / mL to approximately 100 mg / mL. 40 mg / mL, approximately 40 mg / mL to approximately 50 mg / mL, approximately 50 mg / mL to approximately 60 mg / mL, approximately 60 mg / mL to approximately 70 mg / mL, approximately 70 mg / mL to approximately 80 mg / mL, approximately 80 mg / mL to approximately 90 mg / mL, or approximately 90 mg / mL to approximately 100 mg / mL. In certain formulations, ethanol is optionally present in the pharmaceutical formulation at concentrations of approximately 20 mg / mL, approximately 30 mg / mL, approximately 40 mg / mL, approximately 50 mg / mL, approximately 60 mg / mL, approximately 70 mg / mL, and approximately 80 mg / mL. In certain formulations, ethanol is optionally present in the pharmaceutical formulation at a concentration of approximately 40 mg / mL to approximately 100 mg / mL or approximately 20 mg / mL to approximately 40 mg / mL. In certain formulations, ethanol is optionally present in the pharmaceutical formulation at a concentration of less than 40 mg / mL. In some formulations, ethanol is present in pharmaceutical formulations at concentrations of approximately 20 micrograms / mL to approximately 20 mg / mL, such as approximately 20 micrograms / mL to approximately 200 micrograms / mL, approximately 200 micrograms / mL to approximately 500 micrograms / mL, approximately 500 micrograms / mL to approximately 1 mg / mL, approximately 1 mg / mL to approximately 10 mg / mL, approximately 10 mg / mL to approximately 20 mg / mL, approximately 20 micrograms / mL, approximately 100 micrograms / mL, approximately 200 micrograms / mL, approximately 400 micrograms / mL, approximately 600 micrograms / mL, approximately 800 micrograms / mL, approximately 1 mg / mL, approximately 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 12 mg / mL, about 14 mg / mL, about 16 mg / mL, about 18 mg / mL, or about 20 mg / mL. In some formulations, ethanol is optionally present in the pharmaceutical formulation at concentrations of approximately 1 µg / mL to approximately 20 µg / mL, such as approximately 1 µg / mL to approximately 5 µg / mL, approximately 5 µg / mL to approximately 10 µg / mL, approximately 10 µg / mL to approximately 15 µg / mL, approximately 15 µg / mL to approximately 20 µg / mL, approximately 5 µg / mL to approximately 10 µg / mL, approximately 1 µg / mL, approximately 2 µg / mL, approximately 3 µg / mL, approximately 4 µg / mL, approximately 5 µg / mL, approximately 6 µg / mL, approximately 7 µg / mL, and approximately 8 µg / mL. micrograms / milliliter, about 9 micrograms / milliliter, about 10 micrograms / milliliter, about 11 micrograms / milliliter, about 12 micrograms / milliliter, about 13 micrograms / milliliter, about 14 micrograms / milliliter, about 15 micrograms / milliliter, about 16 micrograms / milliliter, about 17 micrograms / milliliter, about 18 micrograms / milliliter, about 19 micrograms / milliliter, or about 20 micrograms / milliliter. In certain formulations, ethanol is optionally present in the pharmaceutical formulation at a concentration of approximately 2 micrograms / milliliter to approximately 10 micrograms / milliliter. In certain formulations, ethanol is optionally present in the pharmaceutical formulation at a concentration of approximately 5 micrograms / milliliter. In the pharmaceutical formulations mentioned here, the aqueous formulation is usually made in a sodium chloride saline solution, which can be of a concentration of about 0.1% w / w to about 5% w / w (e.g., about 0.1% w / w to about 0.5% w / w, about 0.5% w / w to about 1% w / w, about 1% w / w to about 2% w / w, about 2% w / w to about 3% w / w, about 3% w / w to about 4% w / w, or about 4% w / w to about 5% w / w). In some embodiments, the sodium chloride saline solution is of a concentration of approximately 0.5% w / w to approximately 1% w / w (e.g., approximately 0.6% w / w, approximately 0.7% w / w, approximately 0.8% w / w, approximately 0.9% w / w). In some versions, the pharmaceutical formula mentioned here includes: (a) A radioactive conjugate of 225Ac or a pharmaceutically acceptable salt thereof, The radioactive conjugate of 225Ac includes 225Ac chelated with the following structure: , Where the radioactive conjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical formulation at a concentration of 7-9 micrograms / milliliter; (b) Sodium acetate is present in the pharmaceutical formulation at a concentration of 7-8 mg / mL, (c) Sodium ascorbate L is present in the pharmaceutical formulation at a concentration of 51-54 mg / mL; and (d) Diethylene triamine pentaacetate (DTPA), where DTPA is the pentasodium salt of diethylene triamine pentaacetic acid, present in the pharmaceutical formulation at a concentration of 51-54 micrograms / milliliter. In some incarnations, the pharmaceutical formulation has a pH of approximately 3 to approximately 9 (such as 4 to 9, 5 to 9, 3 to 8, 4 to 8, or 5 to 8). The pH of the pharmaceutical formulation may be approximately 3.5, 4.0, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9 or 9.0, or within the range of either. In certain formulations, the pharmaceutical formulation has a pH of approximately 5 to approximately 8. In some embodiments, the pharmaceutical formulation retains at least 90% (e.g., at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 72 hours (e.g., after 96 hours, after 120 hours, after 144 hours, after 168 hours, after 192 hours, after 216 hours, or after 240 hours) at approximately 2°C to approximately 25°C (e.g., approximately 2°C to approximately 5°C, approximately 2°C to approximately 8°C, approximately 2°C to approximately 10°C, approximately 10°C to approximately 15°C, approximately 15°C to approximately 20°C, or approximately 20°C to about 25°C) as determined by radioactive thin-layer chromatography (TLC). In certain embodiments, the pharmaceutical formulation retains not less than 90% (e.g., not less than 92%, not less than 94%, not less than 95%, not less than 96%, not less than 97%, not less than 98%, or not less than 99%) of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7-10 days (e.g., after 7 days, after 8 days, after 9 days, or after 10 days) at approximately 2°C to approximately 25°C (e.g., approximately 2°C to approximately 5°C, approximately 2°C to approximately 8°C, approximately 2°C to approximately 10°C, approximately 10°C to approximately 15°C, approximately 15°C to approximately 20°C, or approximately 20°C to approximately 25°C) as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains not less than 90% (e.g., not less than 92%, not less than 94%, not less than 95%, not less than 96%, not less than 97%, not less than 98%, or not less than 99%) of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7-10 days (e.g., after 7 days, after 8 days, after 9 days, or after 10 days) at approximately 2°C to approximately 8°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains not less than 90% (e.g., not less than 92%, not less than 94%, not less than 95%, not less than 96%, not less than 97%, not less than 98%, or not less than 99%) of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7-10 days (e.g., after 7 days, after 8 days, after 9 days, or after 10 days) at approximately 20°C to approximately 25°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 95% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 3 days at approximately 2°C to approximately 8°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 95% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 3 days at approximately 20°C to approximately 25°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 95% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7-10 days at approximately 2°C to approximately 8°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 95% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7-10 days at approximately 20°C to approximately 25°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 99% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 3 days (or 72 hours) at approximately 2°C to approximately 8°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 98% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7 days (or 168 hours) at approximately 2°C to approximately 8°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 90% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 10 days (or 240 hours) at approximately 2°C to approximately 8°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 99% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 3 days (or 72 hours) at approximately 20°C to approximately 25°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 98% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 7 days (or 168 hours) at approximately 20°C to approximately 25°C as determined by radioactive TLC. In certain embodiments, the pharmaceutical formulation retains at least 90% of the radioactive conjugate of intact 225Ac or the pharmaceutically acceptable salt thereof after 10 days (or 240 hours) at approximately 20°C to approximately 25°C as determined by radioactive TLC. This disclosure also includes a method for preparing the aforementioned 225Ac-PSMA I&T formulation, where the method involves: (a) PSMA I&T was radiolabeled with 225Ac in a reaction buffer solution in the absence of the gentisate compound, where the reaction buffer solution contained sodium acetate and sodium ascorbate L; (b) Heating the mixture from step (a) for a predetermined time to form a radiolabeled product; and (c) Mix the radiolabeled product with the formula buffer solution to form the 225Ac-PSMA I&T formulation, where the formula buffer solution contains sodium ascorbate L and the pentasodium salt of diethylenediaminepentaacetic acid. In certain embodiments, the 225Ac used in the radiolabeling step (a) is reconstituted in an HCl solution with a concentration of less than 0.05 M (e.g., 0.04 M, 0.03 M, 0.02 M, 0.01 M, 0.005 M, 0.004 M, 0.003 M, 0.002 M, or 0.001 M). In certain incarnations, the gentisate compound is gentisic acid, and therefore step (a) is carried out in the absence of gentisic acid. In certain incarnations, the pre-set heating time in step (b) is less than 25 minutes (e.g., 20 minutes, 15 minutes, or 10 minutes). Those undergoing treatment In the methods described here, the pharmaceutical formulation containing a radioactive conjugate of 225Ac in formula I is given to a patient with a cancer that is genetically expressive of PSMA or at risk of developing such cancer. In some incarnations, the patient may have been diagnosed with cancer. The cancer may be primary or metastatic. The patient may have any stage of cancer, such as stage I, stage II, stage III, or stage IV, with or without lymph node involvement and with or without metastases. The methods described may prevent or reduce cancer growth and / or improve the cancer's prognosis (e.g., prevent or reduce metastases). In some incarnations, the patient does not have cancer but has been identified as being at risk for a cancer that genetically expresses PSMA, for example, due to one or more risk factors such as environmental exposure, the presence of one or more genetic mutations or variants, family history, etc. In some incarnations, the cancer expressing PSMA is selected from the group consisting of prostate cancer, breast cancer, colorectal cancer, renal cell carcinoma, bladder cancer, testicular cancer, neuroendocrine cancer, and brain tumor. In some incarnations, the cancer is prostate cancer, such as metastatic castration-resistant prostate cancer (mCRPC). Administration and Dosage therapeutically effective doses In some formulations, therapeutic agents, or pharmaceutical formulations containing them, are administered to a patient in a manner (such as dosage and timing) sufficient to cure or at least partially halt the symptoms and complications of the disorder. In the context of monotherapy (“monotherapy”), the amount sufficient to achieve this purpose is defined as the “therapeutically effective amount” (TEA), which is the amount of the compound sufficient to significantly improve at least one symptom associated with the disease or medical condition. The TEA typically varies depending on the treatment. For known therapeutic agents, the relevant TEAs may be known or readily quantifiable by an expert in the field. For example, in cancer treatment, an agent or compound that reduces, prevents, delays, inhibits, or stops any symptom of a disease or condition is considered therapeutically effective. A therapeutically effective amount of an agent or compound does not need to be able to cure the disease or condition, but it will provide treatment for the disease or condition such that its onset is delayed, impeded, or prevented; its symptoms are improved; its course is altered; or, for example, it is less severe or recovery is accelerated in the individual. For instance, a treatment may be therapeutically effective if it causes the cancer to regress or slow its growth. The effective dosage regimen (e.g., the amount of each treatment, the relative timing of treatments, etc.) for these uses may depend on the severity of the disease or condition, the patient's weight, and their overall health. For example, the therapeutically effective amount of a particular formulation containing a therapeutic agent applied to mammals (e.g., humans) may be determined by an experienced practitioner, taking into account individual differences in age, weight, and mammalian condition. Because some conjugates in this formulation exhibit enhanced ability to target and retain cancer cells, the dosage of these compounds may be less than (e.g., less than or equal to approximately 90%, 75%, 50%, 40%, 30%, 20%, 15%, 12%, 10%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of) the equivalent dose required to achieve a therapeutic effect of the unconjugated agent. Therapeutically effective and / or optimal amounts can also be determined experimentally by an expert in the field. A single or multiple administrations of a radioactive preparation or combination (such as a pharmaceutical formulation containing a radioactive therapeutic agent or conjugate described here) may be performed, with the dosage levels and pattern selected by the treating physician. The dosage schedule and adjustments may be made based on the severity of the disease or condition of the patient being treated, which may be monitored throughout the treatment period according to methods commonly practiced by clinicians or those described here. In some incarnations, the radioactive pharmaceutical is given in a single dose. In other incarnations, the radioactive pharmaceutical is given more than once, i.e., in multiple doses. When the radioactive pharmaceutical is given more than once, the dose for each administration may be the same or different. In some formulations, formulations (such as those containing radioactive conjugates) are administered for radiotherapy planning or diagnostic purposes. When administered for radiotherapy planning or diagnostic purposes, formulations may be given to a patient at a diagnostically effective dose and / or a therapeutically effective dose. In some formulations, an initial dose of the identified conjugate or a formulation thereof (such as a pharmaceutical formulation) is administered at a therapeutically effective dose, followed by a second dose of the identified conjugate or a formulation thereof (such as a pharmaceutical formulation) at a therapeutically effective dose. Pharmaceutical formulations containing one or more agents (such as the radioactive conjugate of 225Ac) can be formulated for use according to the methods and regimens revealed in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers may also be included in the formulation to achieve a suitable formulation. Examples of suitable formulations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed., 1985. For a brief review of drug delivery methods, see, for example, Langer (Science 249:1527–1533, 1990). Formulas Pharmaceutical formulations can be formulated for injection, intranasal, topical, or oral administration, such as via transdermal means, for prevention and / or treatment. They can be administered non-injectionally (e.g., intravenously, intramuscularly, or subcutaneously), orally, orally, orally, or intraarticularly, or intra-articularly in areas affected by vascular or cancerous conditions. Additional routes of administration include intravascular, intra-arterial, intratumoral, intraperitoneal, intradural, intranasal, intraocular, intrasclera, intraorbital, intracanal, rectal, topical, or aerosol inhalation. Extended administration, such as by depot injections, implants, or corrosive components, is also a specific consideration.Suitable formulations include those containing agents (such as the compounds disclosed here) dissolved or suspended in an acceptable carrier, preferably aqueous, such as water, buffered water, saline, or PBS, among others, for non-intravenous administration. Formulations may contain acceptable pharmaceutical excipients to approximate physiological conditions, such as pH adjusting agents, buffer solutions, tonicity adjusting agents, wetting agents, or antiseptics, among others. In some formulations, formulations are designed for oral administration; for example, formulations may contain inert ingredients such as binders or fillers to formulate a unit-dose form, such as a tablet or capsule. In some formulations, formulations are designed for topical administration; for example, formulations may contain inert ingredients such as solvents or emulsifiers to formulate a cream, ointment, gel, paste, or eye drop. Preparations can be sterilized, for example, by conventional sterilization techniques or aseptic filtration. Aqueous solutions can be filled for use as is or freeze-dried, with the freeze-dried preparation being combined with a sterile aqueous carrier before administration. The pH of preparations is typically between 3 and 11, preferably between 5 and 9 or between 6 and 8, with 6 and 7 being the most desirable, such as 6 to 6.5. Effects Therapeutic effect refers to the desired or beneficial effect of a drug or medical treatment in treating a disease, condition, or symptom. It is the intended effect that the drug or treatment is designed to produce in order to improve the patient's health or well-being. The therapeutic effect of the drug, or pharmaceutical formulation as disclosed here, may include symptom relief, treatment or cure of disease, prevention of a condition from worsening, or improvement of general health and quality of life. The therapeutic effect for cancer patients depends on the type of cancer and the stage of the disease. The goal of cancer treatment is to eliminate or control cancer cells while minimizing damage to healthy, normal cells in the body. In some cases, the therapeutic effect includes a reduction in tumor size, stabilization of tumor size, or a decreased rate of tumor growth. In other cases, the therapeutic effect includes a reduction in the rate of disease recurrence or metastasis. Examples Materials: The compounds used in the pharmaceutical formulations described here were manufactured from commercially available chemicals and / or from compounds described in chemical references, following standard organic synthesis techniques known to those experienced in this field. Commercially available chemicals can be obtained from standard commercial sources including, but not limited to, ABX Advanced Biochemical Compounds GmbH (Radeberg, Germany), Acros Organics (Pittsburgh, PA), Apin Chemicals Ltd. (Milton Park, UK), Avidity Science (USA), Avocado Research (Lancashire, UK), BDH, Inc. (Toronto, Canada), Bionet (Cornwall, UK), Chem Service Inc. (West Chester, PA), Crescent Chemical Co. (Haupog, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Frontier Scientific (Logan, UT), and ICN Biomedicals, Inc.(Costa Mesa, California), ITM (Munich, Germany), Key Organics (Cornwall, UK), Lancaster Synthesis (Wyndham, New Hampshire), Parish Chemical Co. (Oream, Utah), Pfaltz & Bauer, Inc. (Waterbury, Connecticut), Polyorganix (Houston, Texas), Pierce Chemical Co. (Rockford, Illinois), Sigma-Aldrich (USA), Spectrum Quality Product, Inc. (New Brunswick, New Jersey), TCI America (Portland, Oregon), Trans World Chemicals, Inc. (Rockville, Maryland), VWR (Radnor, Pennsylvania, USA), Wako Chemicals USA, Inc. (Richmond, Virginia), and Wuxi-Apptech Inc. (Shanghai, China). Example 1. Preparation of pharmaceutical formulations Formula I compounds are small antiparticle molecules that target PSMA and can be radiolabeled with a radionuclide such as actinium-225 (225Ac) to form radiopharmaceuticals chelated with radionuclides. The following documents are available for the synthesis of Formula I compounds or radiopharmaceuticals chelated with the corresponding radionuclides: Weineisen M, et al. EJNMMI Research, 2014, 4:63; Weineisen M, et al. J Nucl Med 2015, 56:1169–1176; US11,129,912 B1; and WO 2018 / 108287 Al. Pharmaceutical formulations containing a radioactive conjugate chelated with 225Ac in formula I can be prepared by following or referring to the protocols specified below. To prepare a 0.001 M HCl solution: Add 4.2 µL of concentrated hydrochloric acid (TraceSelect or equivalent) to 37 mL of water (W8-1), and mix until thoroughly homogeneous. Use a pH meter to ensure the pH of the buffer solution is 3.0 ± 0.5. Preparation of a 0.05 M HCl solution: 220 microliters of concentrated hydrochloric acid (TraceSelect or equivalent) are added to 40 milliliters of water (W8-1), and the solution is mixed until it is completely homogeneous. To prepare a buffer solution for dissolving sodium acetate: Transfer 3.9–4.3 g of sodium acetate to a 150 mL Biotainer. Add 50 mL of water (W8-1) to the container using a suitable-size disposable serological pipette, followed by the addition of 68 µL of concentrated hydrochloric acid (TraceSelect or equivalent). Mix the solution until thoroughly homogeneous. Use a pH meter to ensure the buffer solution has a pH of 6.5 ± 0.3. Preparation of a buffer solution for the sodium acetate-sodium ascorbate reaction: 0.25–0.27 g of sodium ascorbate and 3.9–4.3 g of sodium acetate are transferred to a 50 mL conical tube. 50 mL of water (W8-1) is added to the tube using a suitable-size disposable serological pipette, followed by the addition of 65 µL of concentrated hydrochloric acid (TraceSelect or equivalent). The solution is mixed until thoroughly homogeneous. A pH meter is used to ensure that the pH of the buffer solution is 6.5 ± 0.3. Preparation of a buffer solution for the formulation of ascorbate-DTPA: 17.9–18.1 g of sodium ascorbate L is transferred to a 500 mL receiving bottle. 300 mL of water (W8-1) is added to the receiving bottle using an appropriately sized serological pipette, followed by the addition of 45 µL of pentasodium-DTPA solution (~40% in H₂O) using an appropriately sized calibrated pipette. 7.5 mL of 0.05 M hydrochloric acid is added to the receiving bottle using an appropriately sized disposable serological pipette. The receiving bottle is then sealed, and the resulting solution is mixed until thoroughly homogeneous. A pH meter is used to ensure that the pH of the buffer solution is 6.5 ± 0.3. Reconstitution of the Ac-225 vial: A calibrated pipette is used to transfer a 0.001 M HCl solution into a V-shaped vial containing Ac-225 (the source vial [Ac-225]) such that the radioactivity concentration in the source vial is 2.04 µCi / µL. At least 14 hours are allowed before proceeding to the next step. The entire solution is then transferred from the source vial [Ac-225] into the reaction tube. At least 2 hours are allowed before analyzing the reaction tube and recording the radioactivity value in µCi. Preparation of PSMA I&T Buffer Solution: Dissolution buffer (DB) is added to a vial of PSMA I&T producing agent to obtain a 1 mg / mL solution. The vial is stirred for thirty seconds, and the solution is stirred several times until it is completely dissolved and a homogeneous solution is obtained. Radiolabeling: The PSMA I&T buffer solution described above is transferred to an intermediate flask so that the volume-to-radioactivity ratio in the reaction tube is 4.2 µC / µL. Solvent buffer (DB) and sodium acetate-sodium ascorbate reaction buffer (RB) are added to the intermediate flask to obtain a mixture containing equal volumes of DB and RB, where the total volume-to-radioactivity ratio in the intermediate flask is 2.8 µL / µC. The entire solution is then transferred from the intermediate flask to the reaction tube. The contents of the reaction tube are gently stirred to ensure adequate mixing before heating on a Thermomixer at 90°C for 15 minutes. The reaction tube is then transferred to a lead container and left at room temperature for 5–10 minutes. To prepare the final product: The entire contents of the "reaction" tube are transferred using an appropriately sized syringe into the final product vial labeled "Total Product of Ac-225-PSMA-I&T." A buffer solution for the ascorbate-DTPA formulation is then added using an appropriately sized syringe, at a volume 10 times that of the RB and DB added in the previous step. The solution is stirred slowly and carefully for 30 seconds to ensure it is thoroughly mixed in the "Total Product of Ac-225-PSMA-I&T" vial. The Ac-225-PSMA-I&T total product vial is stored in a lead container labeled "Ac-225-PSMA-I&T Total Product Vial" at 2–8°C for at least 14 hours. The Ac-225-PSMA-I&T total product vial is analyzed in a dose-calibrating apparatus, and the radioactivity value of the final product is recorded in microcuries. Table 1 below shows a pharmaceutical formulation prepared according to the protocols mentioned above. Table 1. Illustrative formulas for pharmaceutical composition Component Quantity per milliliter Function Ac-225-PSMA-I&T; Total peptide (including metal complexes) 0.85-1.26 MPC; 5-22 µg drug substance Water is not available as a solvent Sodium acetate 7.94 mg regulatory agent Sodium ascorbate L 52.1 mg Radiation shielder / regulator Pentasodium salt of diethylenediaminepentaacetic acid (DTPA) 52.2 micrograms, metal chelating agent Example 2. Evaluating the stability of the structures The stability of the pharmaceutical formulation is assessed according to the protocol mentioned below. The final aggregate product containing the above-mentioned 225Ac-PSMA-I&T is used in a stability test, in a glass container. The test sample is assessed for stability by storing it vertically in a shielded container at the appropriate storage temperature. The storage location, date, and time corresponding to the batch number are recorded. Before the expiry date and time (7 days from the manufacturing date), the test sample is removed from the storage location for testing and allowed to reach room temperature for at least 30 minutes. The date and time of sample removal are recorded for the corresponding batch number. Temperature monitoring data for the relevant time period of the test sample storage location is used to verify the absence of temperature deviations. The stability of the test sample is assessed based on the quality characteristics shown in Table 2 below. Table 2. Stability and Quality Characteristics of Pharmaceutical Formulations Quality characteristics of the method Appearance Visual inspection pH scale Concentrating radioactivity; Dose calibrator Chemical content HPLC-UV Chemical purity HPLC-UV Chemical radioactivity purity by HPLC, HPLC-gamma counter Radiochemical impurities detected by HPLC using an HPLC-gamma counter Chemical radioactivity by TLC radioactive detector Sterilization, direct vaccination To assess stability, a pharmaceutical formulation with a radioactivity of 1.26 mCi, a radioactivity concentration of 28 µCi / mL, a molar radioactivity of 5.24 µCi / nMol, and a radiochemical purity of 99.5% was prepared. Following the stability protocol described above, this pharmaceutical formulation exhibited the following stability values as determined by radioactive thin-layer chromatography (TLC): The pharmaceutical formulation retained 99.0% of the intact 225Ac-PSMA-I&T after 7 days at a temperature of 2-8°C. Tables 3-6 below include some of the pharmaceutical formulations for this detection and their stability testing. The batches of formulations listed in Tables 4-6 cover the formulations listed in Table 3. Table 3. Illustrative formulas for pharmaceutical formulations Concentrated component Ac-225- PSMA-I&T 0.85-1.26 MPa / mL Total peptide (including metal complexes) 5-10 µg / mL Water is not available Hydrochloric acid (30-35%) 0.14 mg / ml Sodium acetate 7.94 mg / ml Sodium ascorbate L 52.1 mg / ml Diethylenediaminepentaacetic acid (DTPA), pentasodium salt solution 52.2 micrograms / mL Table 4. Explanatory Formula Batches Batch number, Vial size (ml), RAC (µC / ml at TOC), Directive 1, Time point, Storage conditions, Table [225Ac]-FPI-2265-23004-ST Sterile 20 ml vial 2.5 33 Vertical Day 7+ 6 hours 2-8°C Table 4A [225Ac]-FPI-2265-23005-ST 10 30 Inverted Table 4b [225Ac]-FPI-2265-23006-ST 10 30 Vertical Table 4C [225Ac]-FPI-2265-24007-ST 10 29 Vertical Table 4D Table 4a. Batch of explanatory formulas PPQ 1 Process Performance Evaluation Batch number [225Ac]-FPI-2265-23004-ST Stabilization sample, container closure, sterile 20 ml vial (SEV20) Vertical orientation Volume [225Ac]-FPI-2265 (ml) 2.5 ml Test Admission Standards Results Day 0 (15-30°C) Day 7 (2-8°C) + 6 hours (15-30°C) The concentration of radioactivity at TOC (12 PM, 2 days after the end of synthesis) should be between 23-34 µCi / mL (0.851-1.258 MBcg / mL) 33 µCi / mL (1.221 MBcg / mL) 33 µCi / mL (1.221 MBcg / mL) The specific activity at TOC should be between 2.3 – 6.8 µCi / µg (0.085 – 0.252 MBcg / µg) or 4.1 µCi / µg (0.152 MBcg / µg) - The total peptide content should be between 5 and 10 micrograms / mL. (Note: The reference to 8 micrograms / mL and 8 micrograms / mL appears to be an error and should be disregarded.) The ascorbate content of the total drug product 225Ac-FPI-2265 should be between 38-57 mg / ml and 47 mg / ml. The radiochemical purity by TLC should be ≥95% ROI for 225Ac-FPI-2265. Table 4b. Batch of explanatory formulas PPQ 2 Process Performance Evaluation Batch number [225Ac]-FPI-2265-23005-ST Stabilization sample, container closure, sterile 20 ml vial (SEV20) Direction reversed Size [225Ac]-FPI-2265 (ml) 10 ml Test Admission Standards Results Day 0 (15-30°C) Day 7 (2-8°C) + 6 hours (15-30°C) The concentration of radioactivity at TOC should be between 23-34 microcuries / mL (0.851-1.258 megabecquerels / mL), 29 microcuries / mL (1.073 megabecquerels / mL), and 30 microcuries / mL (1.110 megabecquerels / mL). The specific activity at TOC should be between 2.3 – 6.8 µCi / µg (0.085 – 0.252 MBcg / µg) or 3.6 µCi / µg (0.133 MBcg / µg) - The total peptide content should be between 5-10 micrograms / mL, 8 micrograms / mL, or 7 micrograms / mL. The ascorbate content of the total drug product 225Ac-FPI-2265 should be between 38-57 mg / ml and 47 mg / ml. The radiochemical purity by TLC should be ≥95% for 225Ac-FPI-2265, 100%, or 99%. Table 4C. Batch of explanatory formulas PPQ 3 Process Performance Evaluation Batch number [225Ac]-FPI-2265-23006-ST Stabilization sample, container closure, sterile 20 ml vial (SEV20) Vertical orientation Size [225Ac]-FPI-2265 (ml) 10 ml Test Admission Standards Results Day 0 (15-30°C) Day 7 (2-8°C) + 6 hours (15-30°C) The concentration of radioactivity at TOC should be between 23-34 microcuries / mL (0.851-1.258 megabecquerels / mL) 31 microcuries / mL (1.147 megabecquerels / mL) 30 microcuries / mL (1.110 megabecquerels / mL) The specific activity at TOC should be between 2.3 – 6.8 µCi / µg (0.085 – 0.252 MBcg / µg) or 4.4 µCi / µg (0.163 MBcg / µg) - The total peptide content should be between 5 and 10 micrograms / mL. (Note: The reference to 7 micrograms / mL and 7 micrograms / mL appears to be an error and should be disregarded.) The ascorbate content of the total drug product 225Ac-FPI-2265 should be between 38-57 mg / ml and 47 mg / ml. The radiochemical purity by TLC should be ≥95% ROI for 225Ac-FPI-2265. Table 4D. Batch of explanatory formulas PPQ 4 Process Performance Evaluation Batch number [225Ac]-FPI-2265-24007-ST Stabilization sample, container closure, sterile 20 ml vial (SEV20) Vertical orientation Size [225Ac]-FPI-2265 (ml) 10 ml Test Admission Standards Results Day 0 (15-30°C) Day 7 (2-8°C) + 6 hours (15-30°C) The concentration of radioactivity at TOC should be between 23-34 microcuries / mL (0.851-1.258 megabecquerels / mL) 30 microcuries / mL (1.11 megabecquerels / mL) 29 microcuries / mL (1.073 megabecquerels / mL) The total peptide content should be between 5-10 micrograms / mL, 8 micrograms / mL, or 7 micrograms / mL. The ascorbate content of the total drug product 225Ac-FPI-2265 should be between 38-57 mg / ml and 47 mg / ml. The radiochemical purity by TLC should be ≥95% ROI for 225Ac-FPI-2265. Table 5. Stability results for the process performance evaluation batch for [225Ac]-FPI-2265 [225Ac]-FPI-2265-24024-ST (PPQ5) Table 6. Stability test at 7 and 14 days with storage at 2-8°C Example 3. Administering formulations in cancer treatment The pharmaceutical formulation containing the radioactive conjugate of 225Ac is given to a patient with cancer who is genetically expressing PSMA, according to the protocols mentioned below. Preparing the dose Each dose is prepared individually before administration. The dose calibrator used to measure the dose given to the participant must be the same device used during the calibration process at the start of the study. The dose is prepared sterilely for administration under standard site environmental conditions and standard operating procedures (SOPS). The following procedure is followed for administration preparation: The vial containing the investigational medicinal product (IMP) is allowed to thaw in the lead container on the table at room temperature. The thawing time is estimated at one hour, but sites may use their own judgment when performing thawing to ensure the IMP reaches room temperature before administration. The preparation area must be clean before dispensing. Before putting on gloves, the operator's hands should be washed or sanitized with an alcohol-based hand sanitizer. Once the gloves are on, it is recommended to spray them with 70% isopropyl alcohol (IPA). The bottle stopper is wiped with a sterile cloth moistened with IPA. The wiped stopper is then allowed to dry before piercing. A disposable injection device and needle are used to prepare injections and are assembled immediately before preparation. Injection devices and needles are assembled in a clean environment (or a sterile environment if possible). Sterile connections are not handled directly. The concentration of radioactivity of the product at the time of calibration (TOC). TOC is the date and time at which the supplied radionuclides correspond to the stated radioactivity of the radionuclide. After TOC, the radioactivity decreases. The concentration of radioactivity, and the date and time of calibration, are detailed in the Certificate of Analysis (CoA). A decay correction factor for 225Ac is used to correct the physical decay to the nearest hour. For the administration of [225Ac]-PSMA-I&T, the actual body weight from the participant's general check-up visit is used to calculate the dose of [225Ac]-PSMA-I&T. The estimated volume of [225Ac]-PSMA-I&T to be given to a participant in need is calculated as follows: Volume (ml) = [Dose level (kc / kg) × Body weight in kg] / [Ac-225 degradation correction factor activity concentration at TOC (kc / ml)] administering the dose The pharmaceutical formulation is administered following the procedures for giving [225Ac]-PSMA-I&T to the participant. IMP should not be diluted or given with any other IV fluids, combined with other drugs, or given through an infusion set used at the same time for any purpose other than administering the current IMP. IMP is administered by slow intravenous infusion (IV, 2–5 minutes). For [225Ac]-PSMA-I&T, the dose to be given depends on the participant's weight and study group assignment. The injection can be administered via a peripheral vein (preferred) or a central vein. A three-way valve is recommended during administration to ensure proper intravenous delivery of the product and to guarantee proper priming and flushing. After administration, the line should be thoroughly flushed with normal saline to ensure delivery of the full dose. After administration, the injection line must be removed from the participant and not used for any further procedures. The injection device and all contaminated tubing must be analyzed in the same dose-measuring device to determine the net dose administered. The volume injected, time of administration, and the participant's net dose must be recorded. Other incarnations An expert in the field will recognize or be able to identify many of the equivalents for the specific incarnations mentioned here using only routine experimentation. The following safeguards are intended to include these equivalents.
Claims
A pharmaceutical composition, comprising: (a) a radioconjugate of 225Ac or a pharmaceutically acceptable salt thereof, where the radioconjugate of 225Ac includes 225Ac chelated with a compound of formula I, or a prodrug thereof: (I), where the radioconjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of approximately 1 microgram / mL to approximately 100 micrograms / mL, or in an amount that provides a radioactivity concentration of approximately 10 microcuries / mL to approximately 1000 microcuries / mL of the pharmaceutical composition; (b) Sodium acetate, where sodium acetate is present in the pharmaceutical composition at a concentration of approximately 1 mg / mL to approximately 400 mg / mL; (c) L-sodium ascorbate, where L-sodium ascorbate is present in the pharmaceutical composition at a concentration of approximately 40 mg / mL to approximately 150 mg / mL; and (d) diethylenediamine pentaacetateDiethylenetriaminepentaacetate (DTPA), where DTPA is present in the pharmaceutical composition at a concentration of approximately 5 micrograms / mL to approximately 60 micrograms / mL, is an aqueous formulation and is free of gentisate compounds. The pharmaceutical composition, according to protection element 1, includes the radioconjugate of 225Ac chelated with the following structure: [structure details would be inserted here]. The pharmaceutical composition, according to protection element 1, includes the radioconjugate of 225Ac or its pharmaceutically acceptable salt at a concentration of approximately 7 micrograms / mL to approximately 9 micrograms / mL. The pharmaceutical composition, according to protection element 1, contains sodium acetate at a concentration of approximately 6 mg / mL to approximately 10 mg / mL. The pharmaceutical composition, according to elementProtection level 1, where L-sodium ascorbate is present in the pharmaceutical composition at a concentration of approximately 50 mg / mL. Pharmaceutical composition according to protection level 1, where DTPA is present in the pharmaceutical composition at a concentration of approximately 50 micrograms / mL. Pharmaceutical composition according to protection level 1, where the composition has a pH between 3 and 9. Pharmaceutical composition according to protection level 1, where the composition also contains ethanol, where the ethanol is present in the pharmaceutical composition at a concentration of less than 40 mg / mL or approximately 40 mg / mL to approximately 100 mg / mL. Pharmaceutical composition according to protection level 1, where the composition is ethanol-free. The pharmaceutical composition, according to protection element 1, includes: (a) a radioconjugate of 225Ac or a pharmaceutically acceptable salt thereof, where the radioconjugate of 225Ac includes 225Ac chelated with the structureThe following: (a) Sodium acetate, where the radioconjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of 7-9 micrograms / mL; (b) Sodium ascorbate, where sodium acetate is present in the pharmaceutical composition at a concentration of 7-8 mg / mL; (c) Sodium ascorbate, where sodium acetate is present in the pharmaceutical composition at a concentration of 51-54 mg / mL; and (d) Diethylenetriaminepentaacetate (DTPA), where DTPA is the pentasodium salt of diethylenetriaminepentaacetic acid, where sodium acetate is present in the pharmaceutical composition at a concentration of 51-54 micrograms / mL. The pharmaceutical composition, according to protection element 1, must retain at least 95% of the radioconjugate of 225Ac or its pharmaceutically acceptable salt after 72 hours at approximately 2°C to approximately 25°C, as determined by radioactive thin-layer chromatography.Radiothin-layer chromatography (TLC). The pharmaceutical composition, according to protection element 11, retains at least 95% of the radioconjugate of 225Ac or its pharmaceutically acceptable salt after 7–10 days at approximately 2°C to approximately 25°C, as determined by radioactive TLC. The pharmaceutical composition, according to protection element 1, includes the radioconjugate of 225Ac chelated with the following structure: A pharmaceutical composition consists primarily of: (a) a radioconjugate of 225Ac or a pharmaceutically acceptable salt thereof, where the radioconjugate of 225Ac is chelated with a compound of formula I, or a prodrug thereof: (i) where the radioconjugate of 225Ac or its pharmaceutically acceptable salt is present in the pharmaceutical composition at a concentration of approximately 1 microgram / mL to approximately 100 micrograms / mL, or in an amount that provides a radioactivity concentration of approximately 10(a) Sodium acetate, where sodium acetate is present in the pharmaceutical composition at a concentration of approximately 1 mg / mL to approximately 400 mg / mL; (c) Sodium L ascorbate, where sodium L ascorbate is present in the pharmaceutical composition at a concentration of approximately 40 mg / mL to approximately 150 mg / mL; and (d) Diethylenetriaminepentaacetate (DTPA), where DTPA is present in the pharmaceutical composition at a concentration of approximately 5 micrograms / mL to approximately 60 micrograms / mL, where the pharmaceutical composition is an aqueous formulation and free of the gentisate compound. The pharmaceutical composition, according to protection element 14, is as follows: (a) The radioconjugate of 225Ac consists of 225Ac chelated with the following structure: where the radioconjugate of 225Ac is the radioconjugate or salt.(a) Sodium acetate is present in the pharmaceutical composition at a concentration of 7-9 micrograms / mL; (c) Sodium ascorbate is present in the pharmaceutical composition at a concentration of 7-8 mg / mL; (d) DTPA is the pentasodium salt of diethylenetriaminepentaacetic acid, present in the pharmaceutical composition at a concentration of 51-54 micrograms / mL. A method for preparing the 225Ac-PSMAI&T formulation involves: (a) radiolabeling PSMAI&T with 225Ac in a reaction buffer solution in the absence of the gentisate compound, where the reaction buffer solution contains sodium acetate and sodium ascorbate L; (b) heating the mixture from step (a) for a predetermined time to form a radiolabeled product; and (c) mixing the radiolabeled product with the formula's buffer solution.The formulation buffer solution for 225Ac-PSMAI&T is prepared by using sodium ascorbate and pentasodium salt of diethylenetriaminepentaacetic acid. The method is performed according to protection element 16, where the gentisate compound is gentisic acid. The method is performed according to protection element 16, with a predetermined time of less than 25 minutes. The method is performed according to protection element 16, where 225Ac is reconstituted in an HCl solution with a concentration less than 0.05 M. The method, according to safeguards element 16, requires that the 225Ac-PSMAI&T formulation be gentisate-free and retain at least 99% of the intact 225Ac-PSMAI&T for 7 days or more at approximately 2°C to approximately 8°C, as determined by radiometric TLC. The pharmaceutical composition includes: (a) a radioconjugate of 225Ac or a pharmaceutically acceptable salt thereof, where the radioconjugate of 225Ac includes 225Ac chelated with a compound of formula I, or a prodrug thereof: (I).Where the radioconjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of approximately 1 microgram / mL to approximately 100 micrograms / mL, or in an amount that provides a radioactivity concentration of approximately 10 microcuries / mL to approximately 1000 microcuries / mL of the pharmaceutical composition; (b) sodium acetate, where sodium acetate is present in the pharmaceutical composition at a concentration of approximately 1 mg / mL to approximately 400 mg / mL; (c) L-sodium ascorbate, where L-sodium ascorbate is present in the pharmaceutical composition at a concentration of approximately 40 mg / mL to approximately 150 mg / mL. (d) Diethylenetriaminepentaacetate (DTPA), where DTPA is present in the pharmaceutical composition at a concentration of approximately 5 micrograms / mL to approximately 60 micrograms / mL, where the pharmaceutical composition is an aqueous formulation.
22. A pharmaceutical composition, consisting mainly of: (a) a radioconjugate of 225Ac or a pharmaceutically acceptable salt thereof, where the radioconjugate of 225Ac includes 225Ac chelated with a formula I compound, or a prodrug thereof: (I), where the radioconjugate of 225Ac or the pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of approximately 1 microgram / mL to approximately 100 micrograms / mL, or in an amount that provides a radioactivity concentration of approximately 10 microcuries / mL to approximately 1000 microcuries / mL of the pharmaceutical composition; (b) Sodium acetate, where sodium acetate is present in the pharmaceutical composition at a concentration of approximately 1 mg / mL to approximately 400 mg / mL; (c) Sodium ascorbate L, where sodium ascorbate L is present in the pharmaceutical composition at a concentration of approximately 40 mg / mL to approximately 150 mg / mLmg / mL; and (d) diethylenetriaminepentaacetate (DTPA), where DTPA is present in the pharmaceutical composition at a concentration of approximately 5 µg / mL to approximately 60 µg / mL, where the pharmaceutical composition is an aqueous formulation and is largely free of the gentisate compound.
23. Method according to safeguard element 16, where the 225Ac-PSMAI&T formulation is largely free of the gentisate compound and retains at least 99% of the intact 225Ac-PSMAI&T for 7 days or more at approximately 2°C to approximately 8°C as determined by radiometric TLC.
